Intracameral phenylephrine: the answer to floppy iris syndrome?

Article

Intracameral phenylephrine is a straightforward and effective way to prevent the effects of floppy iris syndrome in patients taking systemic tamsulosin and undergoing cataract surgery.

Intracameral phenylephrine is a straightforward and effective way to prevent the effects of floppy iris syndrome in patients taking systemic tamsulosin and undergoing cataract surgery, according to a study published in the March issue of Eye.

Avinash Gurbaxani and Richard Packard from the King Edward VII Hospital, Berkshire, UK, examined seven patients who were receiving systemic tamsulosin for benign prostatic hypertrophy. Each subject was given intracameral phenylephrine before capsulorhexis during cataract surgery.

The authors observed that there was a significant reduction in the mobility of the iris, reduction in the expected fluttering and sustained papillary dilation.

The results of this study suggest that intracameral phenylephrine can be a useful tool for preventing the effects of floppy iris syndrome in patients receiving systemic tamsulosin while undergoing cataract surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.